Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02393794Phase 1Active Not Recruiting

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Role: lead

NCT06603597Recruiting

HER2-positive Breast Cancer Registry

Role: lead

NCT02379247Phase 1Completed

BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

Role: lead

NCT02413320Phase 2Completed

Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer

Role: lead

All 4 trials loaded